Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision To Uphold Approval Of Two Generic Versions Of Hetlioz
Refinitiv1分未満で読めます
Vanda Pharmaceuticals Inc VNDA:
VANDA SEEKS FDA COMMISSIONER REVIEW OF OUTGOING CDER DIRECTOR'S DECISION TO UPHOLD APPROVAL OF TWO GENERIC VERSIONS OF HETLIOZ®
ログイン、もしくは永年無料のアカウントを作成して、このニュースを読みましょう